Inhibition of the kinase activity of anaplastic lymphoma kinase (ALK) by tyrosine kinase inhibitors (TKIs) has become the first line treatment for patients with advanced non-small cell lung cancer (NSCLC) harboring ALK-positive mutations (1). This evidence concerns the gene ALK and non-small cell lung carcinoma.